Mouse models to study polycystic ovary syndrome: A possible link between metabolism and ovarian function?

Reproductive Biology

Volumn 14, Issue 1, 2014, Pages 32-43

  van Houten, E Leonie A F ^a   Visser, Jenny A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Androgens; Metabolism; Mouse models; Ovary; PCOS; Transgenic and knockout mice

Indexed keywords

ANDROGEN;

ANIMAL; DISEASE MODEL; ENERGY METABOLISM; FEMALE; INSULIN RESISTANCE; METABOLISM; MOUSE; MOUSE MODELS; OBESITY; OVARY; OVARY POLYCYSTIC DISEASE; PCOS; PHYSIOLOGY; REVIEW; TRANSGENIC AND KNOCKOUT MICE;

ANDROGENS; METABOLISM; MOUSE MODELS; OVARY; PCOS; TRANSGENIC AND KNOCKOUT MICE;

ANIMALS; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; INSULIN RESISTANCE; MICE; OBESITY; POLYCYSTIC OVARY SYNDROME;

EID: 84897674038     PISSN: 1642431X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repbio.2013.09.007     Document Type: Review

References (109)

1. Franks S. Polycystic ovary syndrome. N Engl J Med 1995, 333(13):853-861.
2. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004, 19(1):41-47.
3. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285(19):2486-2497.
4. Balen A.H., Conway G.S., Kaltsas G., Techatrasak K., Manning P.J., West C., et al. Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients. Hum Reprod 1995, 10(8):2107-2111.
5. Sir-Petermann T., Codner E., Perez V., Echiburu B., Maliqueo M., Ladron de Guevara A., et al. Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2009, 94(6):1923-1930.
6. Carson R.S., Zhang Z., Hutchinson L.A., Herington A.C., Findlay J.K. Growth factors in ovarian function. J Reprod Fertil 1989, 85(2):735-746.
7. Cook C.L., Siow Y., Brenner A.G., Fallat M.E. Relationship between serum mullerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril 2002, 77(1):141-146.
8. Fallat M.E., Siow Y., Marra M., Cook C., Carrillo A. Mullerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril 1997, 67(5):962-965.
9. Wild R.A. Long-term health consequences of PCOS. Hum Reprod Update 2002, 8(3):231-241.
10. Bronstein J., Tawdekar S., Liu Y., Pawelczak M., David R., Shah B. Age of onset of polycystic ovarian syndrome in girls may be earlier than previously thought. J Pediatr Adolesc Gynecol 2011, 24(1):15-20.
11. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 2002, 16(2):263-272.
12. Blank S.K., McCartney C.R., Marshall J.C. The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome. Hum Reprod Update 2006, 12(4):351-361.
13. Franks S., Gilling-Smith C., Watson H., Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am 1999, 28(2):361-378.
14. Franks S., Mason H., Willis D. Follicular dynamics in the polycystic ovary syndrome. Mol Cell Endocrinol 2000, 163(1-2):49-52.
15. Laven J.S., Mulders A.G., Visser J.A., Themmen A.P., De Jong F.H., Fauser B.C. Anti-Mullerian hormone serum concentrations in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab 2004, 89(1):318-323.
16. Corbould A. Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women. J Endocrinol 2007, 192(3):585-594.
17. Abbott D.H., Dumesic D.A., Franks S. Developmental origin of polycystic ovary syndrome - a hypothesis. J Endocrinol 2002, 174(1):1-5.
18. Eisner J.R., Dumesic D.A., Kemnitz J.W., Abbott D.H. Timing of prenatal androgen excess determines differential impairment in insulin secretion and action in adult female rhesus monkeys. J Clin Endocrinol Metab 2000, 85(3):1206-1210.
19. Robinson J.E., Forsdike R.A., Taylor J.A. In utero exposure of female lambs to testosterone reduces the sensitivity of the gonadotropin-releasing hormone neuronal network to inhibition by progesterone. Endocrinology 1999, 140(12):5797-5805.
20. Blouin K., Boivin A., Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol 2008, 108(3-5):272-280.
21. Dunaif A., Segal K.R., Futterweit W., Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989, 38(9):1165-1174.
22. Escobar-Morreale H.F., San Millan J.L. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab 2007, 18(7):266-272.
23. Poretsky L., Glover B., Laumas V., Kalin M., Dunaif A. The effects of experimental hyperinsulinemia on steroid secretion, ovarian [125I]insulin binding, and ovarian [125I]insulin-like growth-factor I binding in the rat. Endocrinology 1988, 122(2):581-585.
24. Abbott D.H., Tarantal A.F., Dumesic D.A. Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. Am J Primatol 2009, 71(9):776-784.
25. Hogg K., Young J.M., Oliver E.M., Souza C.J., McNeilly A.S., Duncan W.C. Enhanced thecal androgen production is prenatally programmed in an ovine model of polycystic ovary syndrome. Endocrinology 2012, 153(1):450-461.
26. King A.J., Olivier N.B., Mohankumar P.S., Lee J.S., Padmanabhan V., Fink G.D. Hypertension caused by prenatal testosterone excess in female sheep. Am J Phys Endocrinol Metab 2007, 292(6):E1837-E1841.
27. Padmanabhan V., Veiga-Lopez A., Abbott D.H., Recabarren S.E., Herkimer C. Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females. Endocrinology 2010, 151(2):595-605.
28. Shi D., Vine D.F. Animal models of polycystic ovary syndrome: a focused review of rodent models in relationship to clinical phenotypes and cardiometabolic risk. Fertil Steril 2012, 98(1):185-193.
29. Walters K.A., Allan C.M., Handelsman D.J. Rodent models for human polycystic ovary syndrome. Biol Reprod 2012, 86(5). 149, 1-12.
30. Skinner M.K. Regulation of primordial follicle assembly and development. Hum Reprod Update 2005, 11(5):461-471.
31. Bristol-Gould S.K., Kreeger P.K., Selkirk C.G., Kilen S.M., Cook R.W., Kipp J.L., et al. Postnatal regulation of germ cells by activin: the establishment of the initial follicle pool. Dev Biol 2006, 298(1):132-148.
32. Sugiyama N., Barros R.P., Warner M., Gustafsson J.A. ERbeta: recent understanding of estrogen signaling. Trends Endocrinol Metab 2010, 21(9):545-552.
33. Moore A.M., Prescott M., Campbell R.E. Estradiol negative and positive feedback in a prenatal androgen-induced mouse model of polycystic ovarian syndrome. Endocrinology 2013, 154(2):796-806.
34. Roland A.V., Moenter S.M. Prenatal androgenization of female mice programs an increase in firing activity of gonadotropin-releasing hormone (GnRH) neurons that is reversed by metformin treatment in adulthood. Endocrinology 2011, 152(2):618-628.
35. Roland A.V., Nunemaker C.S., Keller S.R., Moenter S.M. Prenatal androgen exposure programs metabolic dysfunction in female mice. J Endocrinol 2010, 207(2):213-223.
36. Sullivan S.D., Moenter S.M. Prenatal androgens alter GABAergic drive to gonadotropin-releasing hormone neurons: implications for a common fertility disorder. Proc Natl Acad Sci U S A 2004, 101(18):7129-7134.
37. Eagleson C.A., Gingrich M.B., Pastor C.L., Arora T.K., Burt C.M., Evans W.S., et al. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 2000, 85(11):4047-4052.
38. Lei L., Jin S., Mayo K.E., Woodruff T.K. The interactions between the stimulatory effect of follicle-stimulating hormone and the inhibitory effect of estrogen on mouse primordial folliculogenesis. Biol Reprod 2010, 82(1):13-22.
39. van Houten E.L., Kramer P., McLuskey A., Karels B., Themmen A.P., Visser J.A. Reproductive and metabolic phenotype of a mouse model of PCOS. Endocrinology 2012, 153(6):2861-2869.
40. Manneras L., Cajander S., Holmang A., Seleskovic Z., Lystig T., Lonn M., et al. A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome. Endocrinology 2007, 148(8):3781-3791.
41. Pirwany I.R., Fleming R., Sattar N., Greer I.A., Wallace A.M. Circulating leptin concentrations and ovarian function in polycystic ovary syndrome. Eur J Endocrinol 2001, 145(3):289-294.
42. Xu A., Chan K.W., Hoo R.L., Wang Y., Tan K.C., Zhang J., et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem 2005, 280(18):18073-18080.
43. Yu W.H., Kimura M., Walczewska A., Karanth S., McCann S.M. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A 1997, 94(3):1023-1028.
44. Karlsson C., Lindell K., Svensson E., Bergh C., Lind P., Billig H., et al. Expression of functional leptin receptors in the human ovary. J Clin Endocrinol Metab 1997, 82(12):4144-4148.
45. Zachow R.J., Weitsman S.R., Magoffin D.A. Leptin impairs the synergistic stimulation by transforming growth factor-beta of follicle-stimulating hormone-dependent aromatase activity and messenger ribonucleic acid expression in rat ovarian granulosa cells. Biol Reprod 1999, 61(4):1104-1109.
46. Lu M., Tang Q., Olefsky J.M., Mellon P.L., Webster N.J. Adiponectin activates adenosine monophosphate-activated protein kinase and decreases luteinizing hormone secretion in LbetaT2 gonadotropes. Mol Endocrinol 2008, 22(3):760-771.
47. Wen J.P., Lv W.S., Yang J., Nie A.F., Cheng X.B., Yang Y., et al. Globular adiponectin inhibits GnRH secretion from GT1-7 hypothalamic GnRH neurons by induction of hyperpolarization of membrane potential. Biochem Biophys Res Commun 2008, 371(4):756-761.
48. Lagaly D.V., Aad P.Y., Grado-Ahuir J.A., Hulsey L.B., Spicer L.J. Role of adiponectin in regulating ovarian theca and granulosa cell function. Mol Cell Endocrinol 2008, 284(1-2):38-45.
49. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86(5):1930-1935.
50. Beloosesky R., Gold R., Almog B., Sasson R., Dantes A., Land-Bracha A., et al. Induction of polycystic ovary by testosterone in immature female rats: modulation of apoptosis and attenuation of glucose/insulin ratio. Int J Mol Med 2004, 14(2):207-215.
51. Demissie M., Lazic M., Foecking E.M., Aird F., Dunaif A., Levine J.E. Transient prenatal androgen exposure produces metabolic syndrome in adult female rats. Am J Phys Endocrinol Metab 2008, 295(2):E262-E268.
52. Hillier S.G., Ross G.T. Effects of exogenous testosterone on ovarian weight, follicular morphology and intraovarian progesterone concentration in estrogen-primed hypophysectomized immature female rats. Biol Reprod 1979, 20(2):261-268.
53. Tyndall V., Broyde M., Sharpe R., Welsh M., Drake A.J., McNeilly A.S. Effect of androgen treatment during foetal and/or neonatal life on ovarian function in prepubertal and adult rats. Reproduction 2012, 143(1):21-33.
54. Edwards D.A. Neonatal administration of androstenedione, testosterone or testosterone propionate: effects on ovulation, sexual receptivity and aggressive behavior in female mice. Physiol Behav 1971, 6(3):223-228.
55. Kamijo T., Mizunuma H., Yamada K., Ibuki Y. In vitro fertilization of androgen sterilized mice. Life Sci 1994, 55(7):527-531.
56. Liu X., Andoh K., Mizunuma H., Kamijo T., Kikuchi N., Yamada K., et al. Effects of recombinant human FSH (rhFSH), urinary purified FSH (uFSH), and hMG on small preantral follicles and tertiary follicles from normal adult and androgen-sterilized female mice. Fertil Steril 2000, 73(2):372-380.
57. Loughlin T., Cunningham S., Moore A., Culliton M., Smyth P.P., McKenna T.J. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1986, 62(1):142-147.
58. Sander V., Solano M.E., Elia E., Luchetti C.G., Di Girolamo G., Gonzalez C., et al. The influence of dehydroepiandrosterone on early pregnancy in mice. Neuroimmunomodulation 2005, 12(5):285-292.
59. Elia E., Sander V., Luchetti C.G., Solano M.E., Di Girolamo G., Gonzalez C., et al. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Mol Hum Reprod 2006, 12(8):475-481.
60. Sander V., Luchetti C.G., Solano M.E., Elia E., Di Girolamo G., Gonzalez C., et al. Role of the N,N'-dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction 2006, 131(3):591-602.
61. Solano M.E., Sander V.A., Ho H., Motta A.B., Arck P.C. Systemic inflammation, cellular influx and up-regulation of ovarian VCAM-1 expression in a mouse model of polycystic ovary syndrome (PCOS). J Reprod Immunol 2011, 92(1-2):33-44.
62. Yaba A., Demir N. The mechanism of mTOR (mammalian target of rapamycin) in a mouse model of polycystic ovary syndrome (PCOS). J Ovarian Res 2012, 5(1):38.
63. Wu R., Fujii S., Ryan N.K., Van der Hoek K.H., Jasper M.J., Sini I., et al. Ovarian leukocyte distribution and cytokine/chemokine mRNA expression in follicular fluid cells in women with polycystic ovary syndrome. Hum Reprod 2007, 22(2):527-535.
64. Schmidt J., Weijdegard B., Mikkelsen A.L., Lindenberg S., Nilsson L., Brannstrom M. Differential expression of inflammation-related genes in the ovarian stroma and granulosa cells of PCOS women. Mol Hum Reprod 2013, 10.1093/molehr/gat051.
65. Fulghesu A.M., Sanna F., Uda S., Magnini R., Portoghese E., Batetta B. IL-6 serum levels and production is related to an altered immune response in polycystic ovary syndrome girls with insulin resistance. Mediators Inflamm 2011, Article ID 389317.
66. El-Mesallamy H.O., Abd El-Razek R.S., El-Refaie T.A. Circulating high-sensitivity C-reactive protein and soluble CD40 ligand are inter-related in a cohort of women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013, 168(2):178-182.
67. Suganami T., Tanaka M., Ogawa Y. Adipose tissue inflammation and ectopic lipid accumulation. Endocr J 2012, 59(10):849-857.
68. Schenk S., Saberi M., Olefsky J.M. Insulin sensitivity: modulation by nutrients and inflammation. Eur J Clin Invest 2008, 118(9):2992-3002.
69. Wu L.L., Dunning K.R., Yang X., Russell D.L., Lane M., Norman R.J., et al. High-fat diet causes lipotoxicity responses in cumulus-oocyte complexes and decreased fertilization rates. Endocrinology 2010, 151(11):5438-5445.
70. Chapman J.C., Min S.H., Freeh S.M., Michael S.D. The estrogen-injected female mouse: new insight into the etiology of PCOS. Reprod Biol Endocrinol 2009, 7:47.
71. Tanriverdi F., Silveira L.F., MacColl G.S., Bouloux P.M. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol 2003, 176(3):293-304.
72. Hefler-Frischmuth K., Walch K., Huebl W., Baumuehlner K., Tempfer C., Hefler L. Serologic markers of autoimmunity in women with polycystic ovary syndrome. Fertil Steril 2010, 93(7):2291-2294.
73. Palacio J.R., Iborra A., Ulcova-Gallova Z., Badia R., Martinez P. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol 2006, 144(2):217-222.
74. Fenichel P., Gobert B., Carre Y., Barbarino-Monnier P., Hieronimus S. Polycystic ovary syndrome in autoimmune disease. Lancet 1999, 353(9171):2210.
75. Novosad J.A., Kalantaridou S.N., Tong Z.B., Nelson L.M. Ovarian antibodies as detected by indirect immunofluorescence are unreliable in the diagnosis of autoimmune premature ovarian failure: a controlled evaluation. BMC Womens Health 2003, 3(1):2.
76. Rojansky N., Roll D., Meirow D. Polycystic ovary syndrome. An autoimmune disease?. J Reprod Med 1997, 42(6):325-328.
77. Petrikova J., Lazurova I. Ovarian failure and polycystic ovary syndrome. Autoimmun Rev 2012, 11(6-7):A471-A478.
78. Janssen O.E., Mehlmauer N., Hahn S., Offner A.H., Gartner R. High prevalence of autoimmune thyroiditis in patients with polycystic ovary syndrome. Eur J Endocrinol 2004, 150(3):363-369.
79. Garelli S., Masiero S., Plebani M., Chen S., Furmaniak J., Armanini D., et al. High prevalence of chronic thyroiditis in patients with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2013, 169(2):248-251.
80. Paavonen T. Hormonal regulation of immune responses. Ann Med 1994, 26(4):255-258.
81. Kumar T.R., Palapattu G., Wang P., Woodruff T.K., Boime I., Byrne M.C., et al. Transgenic models to study gonadotropin function: the role of follicle-stimulating hormone in gonadal growth and tumorigenesis. Mol Endocrinol 1999, 13(6):851-865.
82. Matzuk M.M., DeMayo F.J., Hadsell L.A., Kumar T.R. Overexpression of human chorionic gonadotropin causes multiple reproductive defects in transgenic mice. Biol Reprod 2003, 69(1):338-346.
83. Meehan T.P., Harmon B.G., Overcast M.E., Yu K.K., Camper S.A., Puett D., et al. Gonadal defects and hormonal alterations in transgenic mice expressing a single chain human chorionic gonadotropin-lutropin receptor complex. J Mol Endocrinol 2005, 34(2):489-503.
84. Risma K.A., Clay C.M., Nett T.M., Wagner T., Yun J., Nilson J.H. Targeted overexpression of luteinizing hormone in transgenic mice leads to infertility, polycystic ovaries, and ovarian tumors. Proc Natl Acad Sci U S A 1995, 92(5):1322-1326.
85. Rulli S.B., Kuorelahti A., Karaer O., Pelliniemi L.J., Poutanen M., Huhtaniemi I. Reproductive disturbances, pituitary lactotrope adenomas, and mammary gland tumors in transgenic female mice producing high levels of human chorionic gonadotropin. Endocrinology 2002, 143(10):4084-4095.
86. Britt K.L., Drummond A.E., Cox V.A., Dyson M., Wreford N.G., Jones M.E., et al. An age-related ovarian phenotype in mice with targeted disruption of the Cyp 19 (aromatase) gene. Endocrinology 2000, 141(7):2614-2623.
87. Couse J.F., Bunch D.O., Lindzey J., Schomberg D.W., Korach K.S. Prevention of the polycystic ovarian phenotype and characterization of ovulatory capacity in the estrogen receptor-alpha knockout mouse. Endocrinology 1999, 140(12):5855-5865.
88. Huhtaniemi I., Rulli S., Ahtiainen P., Poutanen M. Multiple sites of tumorigenesis in transgenic mice overproducing hCG. Mol Cell Endocrinol 2005, 234(1-2):117-126.
89. Kero J.T., Savontaus E., Mikola M., Pesonen U., Koulu M., Keri R.A., et al. Obesity in transgenic female mice with constitutively elevated luteinizing hormone secretion. Am J Phys Endocrinol Metab 2003, 285(4):E812-E818.
90. Pasquali R., Stener-Victorin E., Yildiz B.O., Duleba A.J., Hoeger K., Mason H., et al. PCOS Forum: research in polycystic ovary syndrome today and tomorrow. Clin Endocrinol 2011, 74(4):424-433.
91. Devin J.K., Johnson J.E., Eren M., Gleaves L.A., Bradham W.S., Bloodworth J.R., et al. Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 2007, 39(1):9-16.
92. Diebold I., Kraicun D., Bonello S., Gorlach A. The 'PAI-1 paradox' in vascular remodeling. Thromb Haemost 2008, 100(6):984-991.
93. Hernestal-Boman J., Norberg M., Jansson J.H., Eliasson M., Eriksson J.W., Lindahl B., et al. Signs of dysregulated fibrinolysis precede the development of type 2 diabetes mellitus in a population-based study. Cardiovasc Diabetol 2012, 11:152.
94. De Pergola G., De Mitrio V., Giorgino F., Sciaraffia M., Minenna A., Di Bari L., et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes Relat Metab Disord 1997, 21(7):527-535.
95. Gonzalez F., Kirwan J.P., Rote N.S., Minium J. Elevated circulating levels of tissue factor in polycystic ovary syndrome. Clin Appl Thromb Hemost 2013, 19(1):66-72.
96. Koiou E., Tziomalos K., Dinas K., Katsikis I., Kandaraki E.A., Tsourdi E., et al. Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome. Endocr J 2012, 59(1):21-29.
97. Sampson M., Kong C., Patel A., Unwin R., Jacobs H.S. Ambulatory blood pressure profiles and plasminogen activator inhibitor (PAI-1) activity in lean women with and without the polycystic ovary syndrome. Clin Endocrinol 1996, 45(5):623-629.
98. Urbanek M., Sam S., Legro R.S., Dunaif A. Identification of a polycystic ovary syndrome susceptibility variant in fibrillin-3 and association with a metabolic phenotype. J Clin Endocrinol Metab 2007, 92(11):4191-4198.
99. Lansdown A., Rees D.A. The sympathetic nervous system in polycystic ovary syndrome: a novel therapeutic target?. Clin Endocrinol 2012, 77(6):791-801.
100. Dissen G.A., Garcia-Rudaz C., Paredes A., Mayer C., Mayerhofer A., Ojeda S.R. Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans. Endocrinology 2009, 150(6):2906-2914.
101. Lara H.E., Dissen G.A., Leyton V., Paredes A., Fuenzalida H., Fiedler J.L., et al. An increased intraovarian synthesis of nerve growth factor and its low affinity receptor is a principal component of steroid-induced polycystic ovary in the rat. Endocrinology 2000, 141(3):1059-1072.
102. Hill J.W., Elias C.F., Fukuda M., Williams K.W., Berglund E.D., Holland W.L., et al. Direct insulin and leptin action on pro-opiomelanocortin neurons is required for normal glucose homeostasis and fertility. Cell Metab 2010, 11(4):286-297.
103. Marino J.S., Iler J., Dowling A.R., Chua S., Bruning J.C., Coppari R., et al. Adipocyte dysfunction in a mouse model of polycystic ovary syndrome (PCOS): evidence of adipocyte hypertrophy and tissue-specific inflammation. PLoS ONE 2012, 7(10):e48643.
104. Xu Y., Faulkner L.D., Hill J.W. Cross-talk between metabolism and reproduction: the role of POMC and SF1 neurons. Front Endocrinol 2011, 2:98.
105. Varela L., Horvath T.L. Leptin and insulin pathways in POMC and AgRP neurons that modulate energy balance and glucose homeostasis. EMBO Rep 2012, 13(12):1079-1086.
106. Hughesdon P.E. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called "hyperthecosis". Obstet Gynecol Survey 1982, 37(2):59-77.
107. Franks S., Stark J., Hardy K. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum Reprod Update 2008, 14(4):367-378.
108. Champy M.F., Selloum M., Zeitler V., Caradec C., Jung B., Rousseau S., et al. Genetic background determines metabolic phenotypes in the mouse. Mamm Genome 2008, 19(5):318-331.
109. Rice S., Christoforidis N., Gadd C., Nikolaou D., Seyani L., Donaldson A., et al. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005, 20(2):373-381.